Biotech Startups
10,023 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
0 investors
ImmunoMet Therapeutics is a clinical-stage oncology drug developer working to advance lixumistat, a compound targeting oxidative phosphorylation in cancer to address resistance to existing treatments. Founded in 2015 as a spin-off from HanAll Biopharma, the company runs its clinical programs with specialist CROs and partners, including trials at MD Anderson Cancer Center.
0 investors
0 investors
0 investors
0 investors
Immunovus develops software that creates a personal immune "digital twin" to model and forecast an individual's immune trajectory, integrating and interpreting health data such as test results. It targets consumers, clinicians, and pharmaceutical companies, supporting scenario forecasting, personalized clinical trials, drug discovery, and drug repurposing.
0 investors
ImmusanT works on scientific research into the mechanisms of celiac disease, collaborating with investigators from academic and medical research institutions. The company operates in the biotechnology and immunology field focused on this autoimmune condition.
0 investors
0 investors
0 investors
0 investors
Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment. The company's work is validated through peer-reviewed research in leading cardiology journals.
0 investors
Imunon develops DNA-based immunology technologies designed to treat difficult-to-treat conditions including ovarian cancer and infectious diseases. The company's platforms instruct the immune system to generate targeted therapeutic responses.
0 investors
Imvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
0 investors
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches). Its lead candidates include INB-400 and INB-200 for glioblastoma and INB-100 for leukemia patients undergoing bone marrow transplantation.
0 investors
0 investors
0 investors
0 investors
0 investors
Inceptor Bio is a clinical-stage biotechnology company developing cell therapies for cancer, focused on solid tumors. Its OUTLAST platform reprograms T cells during manufacturing to withstand the tumor microenvironment, and its lead candidate is IB-T101.
0 investors
0 investors
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRΞ³-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases. Its lead candidate IDP-023 is being tested in clinical trials for indications such as multiple myeloma, non-Hodgkin's lymphoma, and progressive multiple sclerosis.
0 investors
0 investors